# Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.

> **NCT05358106** · PHASE1 · COMPLETED · sponsor: **Memo Therapeutics AG** · enrollment: 40 (actual)

## Conditions studied

- BK Virus Nephropathy

## Interventions

- **BIOLOGICAL:** AntiBKV
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05358106
- **Lead sponsor:** Memo Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2022-12-05
- **Final completion:** 2023-04-02
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358106, "Assess Safety, Tolerability and Pharmacokinetics of AntiBKV in Healthy Adult Volunteers.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05358106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*